We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gilead Sciences Acquires EpiTherapeutics
News

Gilead Sciences Acquires EpiTherapeutics

Gilead Sciences Acquires EpiTherapeutics
News

Gilead Sciences Acquires EpiTherapeutics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gilead Sciences Acquires EpiTherapeutics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Gilead Sciences, Inc. and EpiTherapeutics ApS have announced the signing of a definitive agreement pursuant to which Gilead has acquired EpiTherapeutics for $65 million, subject to certain purchase price adjustments, to be financed through available cash on hand.

EpiTherapeutics has generated a library of first-in-class, selective small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases. The company’s lead pre-clinical compounds are being studied for the treatment of certain cancers.

“Epigenetics is a promising area of research and the EpiTherapeutics team is a recognized scientific leader in this field,” said Norbert Bischofberger, PhD, Gilead’s Executive Vice President, Research and Development and Chief Scientific Officer. “This therapeutic class represents a strategic fit with our existing research portfolio, including the potential for novel combination approaches. We look forward to working with colleagues from EpiTherapeutics to advance these programs toward clinical development in diseases with significant unmet medical need.”

“EpiTherapeutics has done groundbreaking work in a new therapeutic class of small molecule inhibitors with broad implications across various disease states,” said Martin Bonde, PhD, EpiTherapeutics’ Chief Executive Officer. “We are confident that with Gilead’s acquisition of the company, our discoveries will have the best chance to be developed into therapies that will benefit patients.”

Investors in EpiTherapeutics are NOVO Seeds, SEED Capital, Lundbeckfond Emerge, MS Ventures and Astellas Venture. Back Bay Life Science Advisors of Boston advised EpiTherapeutics on the transaction.

Advertisement